Neuland Laboratories Limited — Others, 04-07-2025: Shareholders meeting

Neuland Laboratories has announced a board meeting on July 30, 2025, to approve the audited financial statements and declare a final dividend of ₹12 per equity share for FY2024-25. The company seeks shareholder approval for the re-appointment of Dr. Christopher M. Cimarusti as a director liable to retire by rotation, recognizing his extensive pharmaceutical R&D expertise. Approval is also sought for the re-appointment of Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director for five years from June 1, 2025, with remuneration capped at 5% of net profits, including a fixed pay range of ₹300-600 lakhs annually plus perquisites. M/s. P.S. Rao & Associates will continue as Secretarial Auditors for five years, and M/s. Nageswara Rao & Co. are re-appointed as Cost Auditors with a fee of ₹4 lakhs for FY2025-26. This meeting is significant for governance and leadership continuity impacting long-term strategy and operational oversight.